- CEPI and Analysis Zero have launched a collaboration to develop NMR-based real-time analytical technology for RNA vaccine manufacturing.
- The project aims to reduce testing timelines and improve efficiency in quality assessment and batch release.
CEPI has announced a seed collaboration with Analysis Zero, a Recipharm company, to advance the use of Nuclear Magnetic Resonance (NMR) as a real-time Process Analytical Technology for RNA vaccine manufacturing. The project is focused on improving how critical quality attributes are measured during production.
The initiative aims to address delays in RNA vaccine manufacturing caused by traditional testing methods, which rely on multiple sequential assays and can take several days to complete. By integrating NMR technology directly into the manufacturing workflow, the collaboration seeks to enable simultaneous, real-time monitoring of multiple quality parameters.
Analysis Zero will contribute expertise in advanced analytical technologies and process integration, while Recipharm will support development and manufacturing capabilities. The approach is designed to shift from off-line testing to in-line measurement, with the goal of accelerating quality assessment and batch release timelines.
The partners stated that the technology could reduce reliance on specialized analytical infrastructure and improve scalability in vaccine production. The solution may also support manufacturing in regions with limited analytical capacity, contributing to broader access to vaccines.
“By shifting from traditional off-line testing to in-line analytical measurement, our new method has the potential to significantly accelerate quality assessment and batch release timelines, enabling faster manufacturing process.”
Aaron Cowley, Chief Scientific Officer at Analysis Zero
